Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma

Anti-cancer Drugs
Olivier MirFrançois Goldwasser

Abstract

Alveolar soft part sarcoma is a rare malignancy usually considered resistant to conventional chemotherapy, but recent data suggest that the multikinase inhibitors sunitinib and cediranib could be active in this setting. A 90-year-old lady with alveolar soft part sarcoma of the leg and lung metastases was started on sunitinib 37.5 mg daily. The treatment was poorly tolerated with grade 3 hypertension and grade 3 thrombocytopenia, which persisted after dose reduction to 25 mg daily. The patient was subsequently started on bevacizumab 10 mg/kg every 2 weeks, resulting in a marked improvement in pain and a partial response on lung metastases for 16 months and ongoing. Agents targeting the vascular endothelial growth factor-signalling pathway seem to exert clinically relevant and prolonged activity against alveolar soft part sarcoma and deserve further evaluation in the treatment of this rare soft tissue sarcoma.

References

Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Sep 9, 2008·Critical Reviews in Oncology/hematology·Joaquim BellmuntUNKNOWN SIOG Taskforce
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Silvia StacchiottiSilvana Pilotti
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Apr 4, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Benoit BlanchetMichel Tod
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Jul 29, 2009·Journal of Pediatric Hematology/oncology·David T VisticaRobert H Shoemaker
Jul 2, 2010·Annals of Surgical Oncology·Elisabetta PennacchioliAlessandro Gronchi
Jan 19, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiS Pilotti
Jul 12, 2011·Pediatric Blood & Cancer·Nuria CondeJaume Mora
Nov 18, 2011·Targeted Oncology·Camille TlemsaniFrançois Goldwasser

❮ Previous
Next ❯

Citations

Feb 22, 2014·Expert Review of Anticancer Therapy·Stefano RadaelliAlessandro Gronchi
Apr 8, 2014·The International Journal of Biochemistry & Cell Biology·Piotr RutkowskiTomasz Świtaj
Jan 21, 2017·Expert Review of Anticancer Therapy·Akash TiwariSameer Bakhshi
Mar 16, 2017·Tumori·Paulina Jagodzińska-MuchaPiotr Rutkowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.